<DOC>
	<DOCNO>NCT00876447</DOCNO>
	<brief_summary>The purpose study ass long-term safety effectiveness botulinum toxin type A patient overactive bladder result spinal cord injury multiple sclerosis . This follow-up study two Allergan sponsor study ( NCT00311376 NCT00461292 ) .</brief_summary>
	<brief_title>A Long-term Follow-up Study Botulinum Toxin Type A Patients With Overactive Bladder Result Spinal Injury Multiple Sclerosis</brief_title>
	<detailed_description>Botulinum toxin Type A 300U discontinue study . Patients remain arm containing botulinum toxin Type A 300U receive botulinum toxin Type A 200U move forward . Also , mask study open-label .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Trichostatin A</mesh_term>
	<criteria>Patient participate study 191622515 191622516 follow criterion fulfil : Patient complete least 52 week precede study . No longer 6 month elapse since completion precede study Patient receive prohibited medication intervene period precede study longterm study . History evidence pelvic urologic abnormality . Previous current diagnosis bladder prostate cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>